Alan W. Shindel, MS MAS, is an Associate Professor of Urology at the University of California, San Francisco (UCSF). He graduated from the school of medicine at Washington University in Saint Louis in 2002. He completed his residency training in urology at Barnes-Jewish Hospital in 2007. After completion of his residency he started a 3-year research and clinical fellowship in andrology (men’s reproductive and sexual health) at UCSF under the direction of Drs. Tom Lue and Ira Sharlip. He joined the faculty of urology at the University of California Davis (UC Davis) in 2010 as an assistant professor of urology; he was promoted to associate professor of urology in 2014. His clinical practice at that time was devoted towards care of patients with sexual concerns, urinary tract symptoms, and chronic pain syndromes. During his time at UC Davis he served in numerous capacities on the medical school admissions committee and was director of the medical student rotations in urology. He was the Inaugural Editor in Chief for Sexual Medicine, an open access journal of the International Society for Sexual Medicine from 2012 to 2015 and served on the board of the Sexual Medicine Society of North America from 2013 to 2015. In 2015 he left UC Davis to serve as a Medical Director at Genomic Health Inc, a manufacturer of genomic based tests for prostate cancer. After two years at Genomic Health Inc. Dr. Shindel returned to UCSF in 2017.

Dr. Aaron Lay is an Assistant Professor at Emory University and is the Chief of Urology at Grady Memorial Hospital. He received his MD degree from Washington University in St Louis. He completed his general surgery internship and urology residency at Brigham and Women's Hospital, and did his endourology and minimally invasive surgery fellowship at the University of Texas Southwestern Medical Center. He has expertise in robotic surgery and kidney stone disease.

Art R. Rastinehad D.O., Northwell Health’s System Director for Prostate Cancer at the Cancer Institute, Vice Chair of Urology at Lenox Hill Hospital

Art Rastinehad, D.O. joined the faculty at Northwell Health in January 2020.  He is the Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair of Urology at Lenox Hill Hospital.  He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery. 

Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principle investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques.  Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health. This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate.  As of May 2016, Dr Rastinehad was the first in the world to perform a gold nano-particle directed ablation using an transperineal MR US Fusion guided focal therapy system.  Dr Rastinehad and his team recently published the first series using this new technology in Proceedings of the National Academy of Science (PNAS).

Dr. Soroush Rais-Bahrami is an Assistant Professor of Urology and Radiology at the University of Alabama at Birmingham as well as being a co-founder of the UAB Program for Personalized Prostate Cancer Care.
He received a Bachelor of Science in Biology and a Bachelor of Arts in Anthropology from the University of Maryland. He later received his Medical Degree from the Johns Hopkins University School of Medicine and then completed residency training in urologic surgery at the Arthur Smith Institute for Urology at the Hofstra North Shore-LIJ School of Medicine in New York. Following residency he further specialized in urologic oncology as a fellow at the National Cancer Institute of the National Institutes of Health.
Dr. Rais-Bahrami has a strong interest in the development and implementation of imaging for the diagnosis, staging, and treatment of urologic cancers as well as developing, improving, and employing robotic and minimally-invasive techniques for the treatment of urologic malignancies. 

Sarah Psutka MD, MSc is a urologic oncologist and Assistant Professor of Urology at the University of Washington. She received her AB in Biology from Harvard College in 2003 and her MD from Harvard Medical School in 2007. She then completed an internship in General Surgery and Residency in Urology at the Massachusetts General Hospital in 2013. During this time, she completed the Clinical Effectiveness Research Program at the Harvard School of Public Health. She subsequently completed a Society of Urologic Oncology Fellowship in Urologic Oncology at the Mayo Clinic, and concurrently obtained her Masters in Clinical and Translational Science from the Mayo School of Graduate Medical Education in 2015. Following completion of her training, she joined the staff of the John H. Stroger Jr. Hospital of Cook County in Chicago where she served as the Director of Urologic Oncology. During this time, Dr. Psutka also was named Assistant Professor of Urology at the Northwestern Feinberg School of Medicine where she conducted clinical research in Bladder Cancer and taught resident trainees. In 2018, she was recruited to join the faculty of the University of Washington, where she now practices as a Urologic Oncologist. Her clinical practice is focused on the treatment of bladder cancer, renal cell carcinoma, and testis cancer. From a research standpoint, her main area of interest is in the study and development of personalized, comprehensive risk stratification measures in patients with urologic malignancies, particularly bladder cancer. She is focused on developing and validating risk stratification programs that will help patients better choose the optimal therapy for them, with the goal of not only improving personalized oncologic outcomes, but also patient reported outcomes such as quality of life. Specifically, she has expertise in the study of precise measurements of frailty and body composition with a focus on sarcopenia. 

Dr. Adam Hittelman is an Associate Professor of Urology and Pediatrics at Yale School of Medicine. He is the Urology Residency Program Director. His clinical practice is focused on Pediatric Urology and congenital urologic disorders. He is the Director of Pediatric Robotic and Minimally Invasive Surgery, Director of the Pediatric Stone Clinic, as well as Co-Director of the Differences of Sexual Development multidisciplinary programs. He had received his BA at the University of California, Berkeley, and subsequently completed his MD and PhD at the New York University School of Medicine. His research interests include the genetic mechanism of patients with Differences of Sexual Development as well as delivery systems and the role of Botulinum Toxin A in the treatment of bladder disorders. 

Bruce J. Schlomer, M.D., is a pediatric urologist at Children’s Health℠ and an assistant professor of urology at UT Southwestern Medical Center.
 

Dr. Schlomer earned his medical degree from Washington University School of Medicine in St. Louis, Missouri, and completed his urology residency at UT Southwestern in Dallas. He then completed his fellowship training in pediatric urology at the University of California San Francisco. Dr. Schlomer is active in medical education and directs the resident pediatric urology education program at Children’s Medical Center Dallas. He also teaches the American Urological Association (AUA) Board Review Course and has served on the AUA Core Curriculum writing committee.

Matthew Rutman, M.D., is the Director of Voiding Dysfunction, Incontinence and Urodynamic Center at New York Presbyterian Hospital/Columbia University Medical Center. He is an Associate Professor of Clinical Urology at Columbia University College of Physicians and Surgeons. He graduated with honors from Emory University and The Chicago Medical School. After completing his residency at William Beaumont Hospital, Dr. Rutman completed a fellowship in female urology, voiding dysfunction, neurourology and urodynamics at the UCLA Medical Center.

Dr. Rutman is board-certified in urology and female pelvic medicine and reconstructive surgery (FMPRS). His practice is limited to male and female voiding dysfunctions including urinary retention, benign prostatic hyperplasia (BPH), interstitial cystitis, prostatitis, urinary incontinence, overactive bladder, neurogenic bladder, urinary tract infections, and reconstructive female urology surgery for vaginal prolapse, urethral diverticulum and vesico-vaginal fistulae. He has authored over  40 book chapters and publications in leading journals and urology textbooks. His clinical and research interests are in male and female incontinence, vaginal prolapse, voiding dysfunction, urodynamics and surgical outcomes.

Dr. Murphy went to medical school at the University of Massachusetts. His residency training was at the University of Connecticut followed by a fellowship in GU trauma and reconstruction at UCSF.  Dr. Murphy is currently on faculty at Washington University School of Medicine.